APR Sept/Oct 2023 - 38

»
BIOPHARMACEUTICAL
»
Automated/Closed Aseptic Processing
Closed processing using closed aseptic transfer technology. Less
stringent environmental requirements (ISO 7/8) and reduced human
interventions. Validation of closed systems and process steps -
functionally " closed " :
* Demonstrate integrity of closed production and aseptic
interfaces between the unit systems throughout lifecycle of use
and under full range of operating conditions
* Recommend performing APS as part of the initial validation of
closed systems
Aseptic Process Scale-Up/Scale-Out
Does the quality system have the capacity to support process scale-up/
scale-out for the manufacturing process: where are the bottle-necks?
* Scalability by size/volume (scale-up)
* Have the aseptic connections changed?
* Has the mass transfer frequency increased?
* APS may be required along with PPQ and media hold studies
* Scalability by adding parallel processing culture systems
(scale-out)
* Simulation to demonstrate capacity is dependent on the risks of
cross-contamination (e.g., facility design, HVAC coverage)
* Define and test at maximum capacity
APS requirements and strategies during process scale-up/scaleout
will be highly dependent on process-specific, facility-specific
risk assessments.
Connecting OT and IT in
Process Applications
Connecting operational technology (OT) with information technology
(IT) in process applications offers many distinct advantages for
processing plants. While technology has made the task easier, there
are still challenges to consider. The following several best practices can
save plant operators a lot of headaches down the road.
It is best practice for connecting OT and IT system integration software
for real-time data communications and the interplay of OT and IT in
modern plants.
The more important one is timely access to information. If you isolate
IT and OT networks, you end up with communications between
them being human-mediated. This means slow communications and
incomplete information that's prone to errors. There's a real advantage
to getting that information directly from OT into IT, and from IT back
into OT. Obviously, for production planning, resource management,
safety monitoring analytics, and fault prediction, not everybody needs
38 |
| September/October 2023
real-time data, but there's a big advantage to not having to wait until
the end of a shift or the end of the day to gain production insights.
One of the rules of communicating between IT and OT is that the
OT network should never have a direct Internet connection. This
means you must route data through IT to get to some of the upand-coming
services such as artificial intelligence (AI) systems15,16
that are cloud-based, or centralized monitoring where there are
multiple, geographically diverse locations, centralized reporting and
aggregation of data from different sources. All these need a mechanism
to get data out to those processing locations, but you don't want that
to be a direct connection out of OT.
This issue stands in the way when companies deal with need to share
data with third parties. They've got suppliers or customers, who want
access to the real-time information coming off their processes, either
for just-in-time supply or for insight into what the process is doing.
Customers want to know what to expect. But they need a transmission
path that isn't exposed to the risks associated with the Internet.
There are three items that could be classified as availability, security
and reliability. Availability is effectively the ability to provide data when
it's required in a form its consumers can use. This means designing
networks that can deliver the data, and choosing protocols that deliver
it in a usable form.
The protocol you choose will affect the network topology. Or, if you
have a certain network topology in mind, that's going to limit the
protocols you can choose. If you want a cloud service, it may expect a
direct connection from OT into the cloud, which is not desirable, and
will impact security.
Security and availability are inversely correlated. The more available
you want to make your data, the less secure it's going to be and vice
versa. So, you must adjust your availability requirements according
to your security needs. When we look at something like industrial
protocols, typically they're not designed with the goal of sharing data
across networks. They're typically client/server designs, which are
inappropriate when the server is in the protected network. You don't
want to reach into the OT network to collect data from a server. You are
going to end up with a mix of protocols depending on the leg of the
journey your data is taking. So, all the way from the PLC or DCS right
up to a cloud or an analysis system, you may need different protocols
for each segment of the path the data traverses.
Then there's a reliability issue-preserving data during disconnections.
If you lose a network connection or you have a hardware failure, you
want to preserve as much data as you can during that time. That
typically means you want to have store-and-forward capability for
data, so you can deal with a network loss. Redundancy is required, so
you should have multiple data paths. If one path goes down, the other
is available.
Once again, the choice of protocol determines how much redundancy
or what sort of store-and-forward you can offer/afford. That again,
limits the protocol choices. If you rely on a particular vendor's
redundancy solution, e.g., it may limit your security capabilities or your
network topology.

APR Sept/Oct 2023

Table of Contents for the Digital Edition of APR Sept/Oct 2023

INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
Facility Tour - Eurofins BioPharma Product Testing
ROUNDTABLE - Drug Delivery
MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
WHITEPAPER - Leveraging Analytical Technology Process for CMC
BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - Cover1
APR Sept/Oct 2023 - Cover2
APR Sept/Oct 2023 - 1
APR Sept/Oct 2023 - 2
APR Sept/Oct 2023 - 3
APR Sept/Oct 2023 - 4
APR Sept/Oct 2023 - 5
APR Sept/Oct 2023 - 6
APR Sept/Oct 2023 - 7
APR Sept/Oct 2023 - 8
APR Sept/Oct 2023 - 9
APR Sept/Oct 2023 - 10
APR Sept/Oct 2023 - 11
APR Sept/Oct 2023 - 12
APR Sept/Oct 2023 - 13
APR Sept/Oct 2023 - 14
APR Sept/Oct 2023 - 15
APR Sept/Oct 2023 - 16
APR Sept/Oct 2023 - 17
APR Sept/Oct 2023 - 18
APR Sept/Oct 2023 - 19
APR Sept/Oct 2023 - 20
APR Sept/Oct 2023 - 21
APR Sept/Oct 2023 - 22
APR Sept/Oct 2023 - 23
APR Sept/Oct 2023 - 24
APR Sept/Oct 2023 - 25
APR Sept/Oct 2023 - 26
APR Sept/Oct 2023 - 27
APR Sept/Oct 2023 - 28
APR Sept/Oct 2023 - 29
APR Sept/Oct 2023 - 30
APR Sept/Oct 2023 - INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
APR Sept/Oct 2023 - 32
APR Sept/Oct 2023 - 33
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
APR Sept/Oct 2023 - 35
APR Sept/Oct 2023 - 36
APR Sept/Oct 2023 - 37
APR Sept/Oct 2023 - 38
APR Sept/Oct 2023 - 39
APR Sept/Oct 2023 - 40
APR Sept/Oct 2023 - 41
APR Sept/Oct 2023 - 42
APR Sept/Oct 2023 - 43
APR Sept/Oct 2023 - FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
APR Sept/Oct 2023 - 45
APR Sept/Oct 2023 - 46
APR Sept/Oct 2023 - 47
APR Sept/Oct 2023 - 48
APR Sept/Oct 2023 - 49
APR Sept/Oct 2023 - QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
APR Sept/Oct 2023 - 51
APR Sept/Oct 2023 - MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
APR Sept/Oct 2023 - 53
APR Sept/Oct 2023 - 54
APR Sept/Oct 2023 - 55
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
APR Sept/Oct 2023 - 57
APR Sept/Oct 2023 - 58
APR Sept/Oct 2023 - 59
APR Sept/Oct 2023 - 60
APR Sept/Oct 2023 - 61
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
APR Sept/Oct 2023 - 63
APR Sept/Oct 2023 - 64
APR Sept/Oct 2023 - 65
APR Sept/Oct 2023 - 66
APR Sept/Oct 2023 - 67
APR Sept/Oct 2023 - CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
APR Sept/Oct 2023 - 69
APR Sept/Oct 2023 - MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
APR Sept/Oct 2023 - 71
APR Sept/Oct 2023 - 72
APR Sept/Oct 2023 - 73
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
APR Sept/Oct 2023 - 75
APR Sept/Oct 2023 - 76
APR Sept/Oct 2023 - 77
APR Sept/Oct 2023 - DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
APR Sept/Oct 2023 - 79
APR Sept/Oct 2023 - 80
APR Sept/Oct 2023 - 81
APR Sept/Oct 2023 - WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
APR Sept/Oct 2023 - 83
APR Sept/Oct 2023 - 84
APR Sept/Oct 2023 - 85
APR Sept/Oct 2023 - Facility Tour - Eurofins BioPharma Product Testing
APR Sept/Oct 2023 - 87
APR Sept/Oct 2023 - 88
APR Sept/Oct 2023 - ROUNDTABLE - Drug Delivery
APR Sept/Oct 2023 - 90
APR Sept/Oct 2023 - 91
APR Sept/Oct 2023 - MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
APR Sept/Oct 2023 - 93
APR Sept/Oct 2023 - An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
APR Sept/Oct 2023 - 95
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
APR Sept/Oct 2023 - 97
APR Sept/Oct 2023 - 98
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
APR Sept/Oct 2023 - 100
APR Sept/Oct 2023 - 101
APR Sept/Oct 2023 - WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
APR Sept/Oct 2023 - 103
APR Sept/Oct 2023 - WHITEPAPER - Leveraging Analytical Technology Process for CMC
APR Sept/Oct 2023 - 105
APR Sept/Oct 2023 - 106
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
APR Sept/Oct 2023 - 108
APR Sept/Oct 2023 - 109
APR Sept/Oct 2023 - MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
APR Sept/Oct 2023 - 111
APR Sept/Oct 2023 - 112
APR Sept/Oct 2023 - 113
APR Sept/Oct 2023 - VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - 115
APR Sept/Oct 2023 - 116
APR Sept/Oct 2023 - 117
APR Sept/Oct 2023 - 118
APR Sept/Oct 2023 - 119
APR Sept/Oct 2023 - 120
APR Sept/Oct 2023 - Cover3
APR Sept/Oct 2023 - Cover4
https://www.nxtbookmedia.com